SPP1 and neoplasm: A study suggests that SPP1 is a predictor of adverse prognosis in HCC patients and that targeting SPP1 might be a potential approach to modulate the tumor microenvironment and enhance response to immunotherapy in HCC (Liu et al., 2022).